Cardiovascular Resource GroupLLY
ImmunologyMetabolicNeurologyOncologyPsychiatry200 cited findings · profile updated 2026-08-26
1192.42 USDnot live — refreshed daily
About Cardiovascular Resource Group
Cardiovascular Resource Group (LLY) has a therapeutic focus that includes oncology. The company's oncology research has included studies on Kisunla (donanemab). Infusion-related reactions (IRR) were observed with donanemab, with an incidence of 8.7% in AACI-PC and 6.9% in Study AACG. Serious hypersensitivity or IRR events occurred in 0.4% of donanemab-treated participants in AACI-PC, compared to 0.1% in placebo. Treatment discontinuation due to IRR was 3.6%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| IRR incidence (donanemab) | 8.7% | Eli Lilly and Company — Kisunla EMA EPAR public assessment report (EME, p.86 |
| Serious hypersensitivity or IRR event (donanemab) in AACI-PC | 0.4% | Eli Lilly and Company — Kisunla EMA EPAR public assessment report (EME, p.88 |
| Treatment discontinuation due to IRR | 3.6% | Eli Lilly and Company — Kisunla EMA EPAR public assessment report (EME, p.103 |
| IRRs in donanemab-treated participants (Study AACG) | 6.9 % | Eli Lilly and Company — Kisunla EMA EPAR public assessment report (EME, p.175 |
| Serious hypersensitivity, anaphylactic, or IRR event (donanemab) | 0.4% | Eli Lilly and Company — Kisunla EMA EPAR public assessment report (EME, p.101 |
| IRR TEAEs severity: severe (All Dona) | 5.1% | Eli Lilly and Company — Kisunla EMA EPAR public assessment report (EME, p.101 |
Key projects
- Kisunla (donanemab)
Infusion-related reactions (IRR) were observed at an incidence of 8.7% with donanemab.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Immunology research library →